Both innate and adaptive immune cells are present in the tumor immune microenvironment: therapies that target innate cells such as agents that block the CD47-SIRPα interaction are being evaluated in the clinic, and checkpoint inhibitor blockade treatments that promote T cell activity are now FDA-approved for several tumor histotypes (1, 3–5). The gene discussed is CD47; the disease is neoplasm.